Rita C. Peters

Climbing out of a reputation hole can start with adopting a quality culture.

While overall industry performance is trending positive, quality failures continue to negatively impact patients and the bio/pharma industry.

The editors welcome technical article contributions from biopharma industry experts.

Half a century after man first walked on the moon, space-based science is exploring benefits for Planet Earth.

FDA and USP take sides in debate on biologic drug standards.

FDA’s annual manufacturing report card shows more quality compliance is needed.

Pharma delivers a positive message with renewed efforts to eradicate malaria.

Promoting patient compliance with drug regimens extends beyond the formulation laboratory.

Do patients get what they pay for when they demand cheaper drugs?

Biosimilars, pricing strategies, and technology investments will influence growth in spending on drugs.

Pricing pressures, investment volatility, and government disfunction greet Biopharma in 2019.

Compensation and professional challenges are key pieces to solving the biopharma employee satisfaction puzzle.

Bio/pharma companies are successfully launching novel therapies; however, the industry still needs to work on manufacturing innovation.

Innovation may capture headlines, but quality programs are the foundation to biopharma success.

Survey results and record attendance may show positive signs for established and emerging biopharma regions.

By adapting techniques from other sciences-and exploring better tools for biologics drug development-researchers are addressing challenges of protein characterization.

Sharing of bioprocessing know-how can help resolve pressing industry problems.

Frustrated by slow market adoption, Gottlieb maps out new plan for biosimilar competition.

In launching FDA’s Biosimilar Action Plan, Gottlieb takes innovator companies to task for delaying competitive biosimilar products.

After 30 years of biologic-drug advances, the industry and patients still have a lot to learn.

Biopharma companies can balance competing demands from patients, investors, and regulators by keeping a focus on science.

By minding gaps in industry knowledge, bio/pharma companies can avoid development pitfalls.

While technology promises advances for healthcare, a skilled workforce is needed to deliver on the potential.

Process understanding and careful assessment of risks are essential in developing viral clearance programs.

More diversified therapies and tighter payer budgets will challenge bio/pharma companies to think outside the industry.

A different perspective on controlling fixed costs of biomanufacturing, based on know-how from other industries, provides a competitive edge, says the CEO of Samsung BioLogics.

Frustrated with high costs and drug shortages, hospitals adopt a DIY approach.

BioPharm International will mark 30 years of biopharma industry progress and challenges in 2018.

Biopharma employees reveal employment objectives, opportunities, and frustrations.

Developing and retaining qualified employees will test biopharma companies and CMOs alike.